This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Testicular cancer

Selwin has overcome

testicular cancer.

Screening could help prevent

him suffering from the

consequences of TD.

Selwin, aged 30

Selwin - cancer treatment
Test me

Patient profile is fictional and for illustrative purposes only.


Are all your testicular cancer survivors routinely screened for symptoms of testosterone deficiency (TD)?


The European Society for Medical Oncology (ESMO) reports that hypogonadism is present in 11-35% of testicular cancer survivors.1 Therefore, in all patient follow up appointments post orchidectomy, ESMO recommends monitoring of total testosterone (TT), luteinizing hormone (LH) and follicle-stimulating hormone (FSH).1

The British Society for Sexual Medicine (BSSM) recommends an annual follow-up to monitor for long-term testicular cancer treatment-related side effects, including monitoring of testosterone and sex hormone binding globulin levels (SHBG).2


Encourage your patients to report symptoms during follow-up appointments

by providing education about potential long-term complications,
such as TD.1

Tools for screening

Men may not always mention all the symptoms of TD that they are experiencing. The Androgen Deficiency in Ageing Males (ADAM) questionnaire and the Ageing Males’ Symptoms (AMS) scale are simple and effective tools that can be quickly filled out during a patient appointment, to help you catch the symptoms of TD.3


  1. Oldenburg J, Fosså SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):125–132.
  2. British Society for Sexual Medicine. Accessed April 2021.
  3. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: